SWTX
FY2027 EPS Estimate
$1.72
FY2027E EPS$1.72
FY2028E EPS$3.90

Analyst Sentiment

Wall St. Consensus
Buy
11 analysts·Moderate coverage
66
Score
7 Buy (64%)4 Hold (36%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
764%
Hold
436%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$47.00
+0.0%
Consensus
$76.00
+61.7%
Bull
$78.00
+66.0%
12-Month Target Range11 analysts
$47.00$76.00$78.00
Current $46.99Consensus
Current Price
$46.99
Upside to Consensus
$29.01

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+37.05%
EPS
FY2028
Rev+6.48%
EPS+126.31%
FY2029
Rev+16.71%
EPS-59.74%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$612M$839M$894M$1.04B
Low$480M$658M$701M$818M
High$758M$1.04B$1.11B$1.29B
EBITDA Avg$-367M$-504M$-536M$-626M
Low$-455M$-623M$-664M$-775M
High$-288M$-395M$-421M$-491M
EBIT Avg$-367M$-504M$-536M$-626M
Low$-455M$-623M$-664M$-775M
High$-288M$-395M$-421M$-491M
Net Income Avg$-86M$76M$289M$116M
Low$-146M$-61M$208M$84M
High$17M$316M$379M$152M
EPS Avg$-0.83$1.72$3.90$1.57
Low$-1.97$-0.82$2.81$1.13
High$0.22$4.27$5.11$2.06
Analysts (Rev / EPS)3 / 32 / 21 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$196M$220M
Low$196M$220M
High$196M$220M
EBITDA Avg$-118M$-132M
Low$-118M$-132M
High$-118M$-132M
EBIT Avg$-118M$-132M
Low$-118M$-132M
High$-118M$-132M
Net Income Avg$-1M$12M
Low$-1M$12M
High$-1M$12M
EPS Avg$-0.02$0.16
Low$-0.02$0.16
High$-0.02$0.16
Analysts (Rev / EPS)2 / 12 / 1

Earnings Surprises

Recent Analyst Actions

Apr 28, 2025Barclays
SpringWorks Therapeutics downgraded to Equal Weight from Overweight at Barclays
Target:$47.00
+1.8%from $46.18
Jan 8, 2025Guggenheim
SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim
Target:$78.00
+89.3%from $41.20
Aug 8, 2024H.C. Wainwright
Spring Works Therapeutics (SWTX) PT Raised to $76 at H.C. Wainwright
Target:$76.00
+124.0%from $33.93
Aug 9, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $94
Target:$94.00
+137.0%from $39.66
May 27, 2022Wedbush
Wedbush Maintains Outperform on SpringWorks Therapeutics, Lowers Price Target to $50
Target:$50.00
+167.1%from $18.72
May 24, 2022Goldman Sachs
Goldman Sachs Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $76
Target:$76.00
+132.1%from $32.74
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.